INTRODUCTION
Main review searches
The main aim of the search will be to systematically identify studies. The following data sources will be searched:
• Bibliographic databases including Cochrane Library (CENTRAL), MEDLINE, EMBASE • Citation lists of relevant studies • Contact with experts in the field • Conference proceedings -any specific paediatric conferences Treatment algorithms; Guidelines • Previous trials unit protocols.
Up to the moment guideline values will be obtained from official websites of national associations for diabetes in each of selected countries.
No language restrictions will be applied. We will take into consideration studies no older than five years. If we find a systematic review and it is reliable one (after critical appraisal) then we will narrow our search date to update the evidence we have. *************************** Making inclusion/exclusion decisions.
Example of search strategy

Database: Embase <1996 to 2013 Week 34> Search Strategy: ------------------------------------------------------------------------------
Three reviewers will independently assess papers for inclusion/exclusion criteria using the title and articles' abstract. Disagreements will be resolved by discussion. Full paper copies of relevant or potentially relevant references will be obtained for detailed examination. Foreign language publications will be screened using English abstracts. Translations will be obtained where necessary or were possible, within the resources and timeframe of the project.
DATA HANDLING
Data extraction strategy
Data will be extracted using a pre-designed data extraction form, by one reviewer and checked by a two other reviewers. Where information is missing authors will be contacted, but within the resources and timeframe of the project. Data from studies with multiple publications will be extracted and reported as a single study, in case of discrepancies the publication with biggest representative population will be utilized.
Methods of analysis
A descriptive analysis of included studies will be undertaken and relevant evidence will be categorised and summarised in tables (excel and word). GLM model for regression analysis will be used since no intervention is assessed. When appropriate, weighted variable will be used e.g. GPD per capita, number of patients included into the study.
Identified research evidence will be appropriately interpreted according to the assessment of methodological strengths and weaknesses and the possibility of potential biases.
The following subgroup analyses will be undertaken:
• High-income countries' HbA1c median values.
• Median value of HbA1c with exclusion of measurements higher than 10%
Data extraction
Standard data extraction table designed for this study will be used. *************************** Database: Ovid MEDLINE(R) <1946 to August Week 2 2013> Search Strategy: Figure 2 Comparison within high-income countries. "6.5" vs. "7.5" group (a) "6.5" vs. "7.0" vs. Characteristics of included studies with data extracted for quantitative analysis. Presented mean values concern the whole population of each study. Studies are presented in order of HbA1c guideline, mean HbA1c and study design. Regarding complications (diabetic ketoacidosis and hypoglycemia) "1" indicates that they occurred more frequently in the study population (specific subset of patients) than the literature reports [119, 120] . Null indicates in these columns on standard frequency. Regarding insulin therapy if more than a half of patients were treated with MDI then a study was appointed with "1" if more than 50% of patients were treated with CSII then a study was appointed with "0". HbA1c -concentration of glycated hemoglobin A1c, GDP -gross domestic product, yrs. 
